MarketInOut Stock Screener Log In | Sign Up

ADARx Pharmaceuticals Inc

NASDAQ • Healthcare • Biotechnology • Quote as of 10/30/2026
ADARx Pharmaceuticals Inc stock price and volume chart

Company Profile

IndustryBiotechnology
SectorHealthcare
ExchangeNASDAQ
Market Capitalization1,882.56 mln
Float45.36 mln

1-Year Forecast

34.25
Transformational upside

Relative Strength

28 / 100
Underperforming

Debt / Equity

0.07
Debt-free

Pre-Tax Margin

-1,678%
Severely loss-making

ROE

-40.62
Deeply negative

ROA

-10.32
Deeply negative

Business Description

ADARx Pharmaceuticals is a San Diego-based clinical-stage biotech company, founded in 2019, that develops RNA-based medicines targeting a wide range of serious diseases. Its lead programs include treatments aimed at hereditary angioedema, stroke prevention, and a liver-focused therapy with the potential to address multiple conditions. The company is also advancing earlier-stage programs targeting obesity and Alzheimer's disease. All of its work is built on a shared technology platform designed to deliver these therapies precisely to the intended tissues in the body.

Key Fundamentals

EPS-1.16
ROE-40.62
RPS0.54
ROIC-160
ROA-10.32
EBITDA, mln-46.97
EV / EBITDA-41.44
EV / EBIT-40.20
Revenue, mln2.89
EV / Revenue675

Quote Details

Last 17.00
Change -0.85 (-4.76%)
Open 18.10
Volume 542,258
Turnover 9,218,386
Average Volume 467,906

Financial Ratios

Pre-Tax Profit Margin-1,678
Current Ratio12.98
Debt / Equity0.07
Price / Sales671

Financial Strength

1-Year Target Price34.25
Short Ratio2.00

Price Performance & Relative Strength

Period Price Performance Relative Strength
1 Week -3.57% 21 / 100   
1 Month -13% 25 / 100   



Disclaimer - Privacy Policy - Terms of Service - Cookies - FAQ - Affiliates - Blog